Changing costs of metastatic non small cell lung cancer in the Netherlands

Autor: Keusters, W R, de Weger, Vincent A, Hövels, A, Schellens, J H M, Frederix, G W J, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Přispěvatelé: Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Jazyk: angličtina
Rok vydání: 2017
Předmět:
Male
Cancer Research
Lung Neoplasms
medicine.medical_treatment
0302 clinical medicine
Cost of Illness
Non-small cell lung cancer
Carcinoma
Non-Small-Cell Lung
Outcome Assessment
Health Care
Disease management
80 and over
030212 general & internal medicine
Non-Small-Cell Lung
Case report form
Average cost
Netherlands
Aged
80 and over
Health Policy
Disease Management
Health Care Costs
Middle Aged
Oncolytic drugs
Oncology
Cost driver
030220 oncology & carcinogenesis
Healthcare policy
Cost of illness
Female
Immunotherapy
Pulmonary and Respiratory Medicine
Adult
medicine.medical_specialty
Antineoplastic Agents
03 medical and health sciences
Outcome Assessment (Health Care)
Internal medicine
medicine
Journal Article
Humans
Intensive care medicine
Lung cancer
Aged
Retrospective Studies
business.industry
Carcinoma
Cancer
Retrospective cohort study
Length of Stay
medicine.disease
Oncolytic virus
Radiation therapy
business
Delivery of Health Care
Zdroj: Lung Cancer, 114, 56. Elsevier Ireland Ltd
Lung Cancer, 114, 56. Elsevier Ireland Ltd.
ISSN: 0169-5002
Popis: Objectives The primary objective of this study was to identify the total intramural cost of illness of metastatic non-small cell lung cancer (NSCLC) in the Netherlands between 2006–2012. Secondary objective was to identify whether changes in cost patterns of metastatic NSCLC have occurred over the last years. Methods Patients diagnosed with metastatic NSCLC between 1-1-2006 and 31-12-2012, who had follow-up to death or the date of data cut-off and no trial participation were included. A structured chart review was performed using a case report form. Data collection started after diagnosis of metastatic NSCLC and ended at death or April first, 2015. Data regarding outpatient visits, clinical attendance, oncolytic drug use, imaging, lab tests, radiotherapy and surgery were collected. Results Sixty-seven patients were included with a median age of 67 years. The median follow-up was 234 days. On average patients had 28 outpatient visits and 11 inpatient days. Oncolytic drugs were administered to 76% of the patients. Mean per patient expenditures amounted up to €17,463, with oncolytic drugs (€6,390) as the main cost driver. In comparison with the time-period of 2003–2005 total per patient per year expenses decreased by 44%. The contribution to total yearly costs of oncolytic drugs increased from 18% to 35%, while costs for inpatient stay decreased from 52% to 28% of total expenditures. Conclusion Outcomes in this study demonstrate that average treatment costs for metastatic NSCLC in the Netherlands Cancer Institute amount to €17,463. Compared to a prior study the average cost for metastatic NSCLC over time in the Netherlands has decreased. A shift of main cost drivers seems to have occurred from inpatient stay, to oncolytic drugs as main contributor. The shift towards treatment cost might become more visible with the introduction of immunotherapy. These results mark the importance of up-to-date cost of illness studies.
Databáze: OpenAIRE
Externí odkaz: